Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

Abstract HER2+ breast cancer (BC) is an aggressive subtype genetically and biologically heterogeneous. We evaluate the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in 154 HER2+ BCs patients who received trastuzumab-based neoadjuvant...

Full description

Bibliographic Details
Main Authors: Sandra Orrù, Emanuele Pascariello, Barbara Pes, Vincenzo Rallo, Raffaele Barbara, Marta Muntoni, Francesca Notari, Gianfranco Fancello, Cristina Mocci, Maria Rosaria Muroni, Paolo Cossu-Rocca, Andrea Angius, Maria Rosaria De Miglio
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-40071-2

Internet

https://doi.org/10.1038/s41598-023-40071-2

Similar Items